(Lidocaine + prilocaine) is under clinical development by Plethora Solutions and currently in Phase II for Premature Ejaculation. According to GlobalData, Phase II drugs for Premature Ejaculation does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Lidocaine + prilocaine) LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Lidocaine + prilocaine) overview
Lidocaine and Prilocaine (Fortacin / Senstend) is a fixed dose combination. It is formulated as a spray for cutaneous and topical route of administration. It is indicated for the treatment of primary premature ejaculation in adult men and is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during penetration). It is under development for the treatment of premature ejaculation in adult man in the US.
Plethora Solutions overview
Plethora Solutions (Plethora), a subsidiary of Regent Pacific is a pharmaceutical company which develops and markets products for the treatment and management of urological disorders.
For a complete picture of (Lidocaine + prilocaine)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
